37 results about "Morphine" patented technology

The invention provides a nucleic acid aptamer for specific recognition of morphine and application of the nucleic acid aptamer, and belongs to the technical field of biosensing and detection. The nucleotide sequence of the nucleic acid aptamer is as shown in SEQ ID NO: 1. The screening method is based on a Capture-SELEX technology and comprises the key steps that streptavidin magnetic beads are used for fixing an ssDNA library, estradiol, deabietic acid and totarol are introduced to serve as reverse screening substances so as to remove non-specific sequences, and finally the high-specificity aptamer is obtained through high-throughput sequencing and affinity determination. The dissociation constant of the aptamer and morphine is 127.31 nM, and the aptamer shows high affinity and high specificity. The invention further relates to application of the aptamer in preparation of a sensor and a kit for detecting morphine, and a new technical means is provided for rapid detection of morphine.

The invention relates to a hybridoma cell strain capable of secreting dextromethorphan monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. The monoclonal antibody secreted by the hybridoma cell strain disclosed by the invention has good sensitivity and specificity on dextromethorphan, wherein the IC50 value on the dextromethorphan is 0.162 ng / mL. The monoclonal antibody provided by the invention has no cross reaction on structural analogues of dextromethorphan, such as fentanyl, thilazine, papaverine, morphine and medetomidine, and has good specificity, so that the dextromethorphan with low concentration can be accurately detected.

The application provides a method for detecting psychotropic drugs in environmental sludge based on acid pretreatment, which comprises the following steps: S1: obtaining a sludge sample to be detected, performing pressurized fluid extraction on the sludge sample to be detected after freeze-drying to obtain an extraction solution, performing solid-phase extraction on the extraction solution to obtain an eluate, and redissolving the eluate to obtain a solution to be detected, wherein the pressurized fluid extraction is performed under the condition of 5 ‰ formic acid water without heating; and S2: performing liquid chromatography mass spectrometry on the solution to be detected to obtain a mass spectrum, wherein the psychotropic drug is one of eptazocine, codeine, AMP, MAMP, MDA, monoacetylmorphine, MDMA, PMMA, fentanyl, norfentanyl, ketamine, norfentanyl, benzoyl eptazocine, cocaine and tramadol, and the method realizes detection of multiple psychotropic drugs in environmental sludge.

The present invention relates to a compound of formula (I), which is a phosphate ester of apomorphine, or a pharmaceutically acceptable salt thereof. The apomorphine phosphate ester according to the invention exhibits remarkably advantageous properties as a therapeutic, including a favorable tolerability, an improved side effect profile, particularly a reduced occurrence of skin nodule formation and panniculitis when administered subcutaneously, as well as pharmacokinetic and metabolic properties rendering it particularly well-suited as an apomorphine prodrug. The invention further relates to the compound of formula (I) for use as a medicament, particularly for use in the treatment of Parkinson's disease.

The present disclosure relates to a method of treatment or prophylaxis of a preterm infant by administering intravenously a therapeutic amount of a composition comprising IGF-1 and IBGBP-3 in combination with a therapy selected from the group comprising: caffeine, fentanyl, fluconazole, gentamicin, insulin, midazolam, morphine, low dose norepinephrine, vancomycin concentrations of 5 mg / ml or less, parenteral nutrition (or a composition for the same use) and combinations thereof.

The invention relates to the technical field of medicines, and discloses a novel light cuspidine type diterpenoid alkaloid compound and application of the novel light cuspidine type diterpenoid alkaloid compound. According to the present invention, the novel C20 selaginine type diterpenoid alkaloids such as the Carmaloidline C, the Carmaloidline D and the Aconialoidline C, which are provided by the present invention, all have significant analgesic effects; wherein the analgesic activity of the Carmaloidline C is the strongest, is superior to that of the positive drug morphine and is obviously superior to that of the positive drug ibuprofen, and the analgesic activity of the Carmaloidline D and the analgesic activity of the Aponiloidline C are superior to that of the positive drug ibuprofen. The medicines can be used for developing analgesic medicines for various acute or chronic pains.

A method, apparatus and computer program product are provided for a compiled standardized measure representative of a subset of prescription transactions associated with a controlled substance. The compiled standardized measures may be used in the prescription domain to notify prescribers of a patient's morphine milligram equivalent (MME) to reduce risks related to drug overdose, abuse, and the like. Historical prescription transactions may be accessed to identify prescriptions classified as an opioid or other controlled substance, and that may likely still be in a patient's possession based upon days supply, such that a daily MME may be calculated. Messaging is provided to the prescriber if the amount exceeds a maximum threshold, and the prescription can be changed accordingly.

The present invention relates to a morphinan-type compound, a preparation method therefor, a composition thereof and the use thereof. Specifically disclosed is a compound I or a pharmaceutically acceptable salt thereof. The morphinan-type compound of the present invention has one or more of the following effect advantages: (1) a relatively high binding affinity for an opioid receptor; (2) a significant agonistic effect on KOR and MOR; (3) good selectivity for a κ receptor; and (4) a good therapeutic effect on inflammatory pain (for example, rapid onset of action or significant analgesic effect).

This disclosure relates to morphinan compounds and derivatives thereof, pharmaceutically acceptable salts, solvates and hydrates thereof, and compositions comprising the compounds, and use of such compounds and compositions in methods of treating diseases and conditions.

The invention discloses a method for measuring morphine content in a cough-relieving and phlegm-reducing pill, and aims to improve the quality standard of the cough-relieving and phlegm-reducing pill and guarantee the medication safety of a patient. The method adopts a high performance liquid chromatography and comprises the following steps: precisely weighing a cough-relieving and phlegm-reducing pill sample, grinding, and carrying out ultrasonic extraction by taking 20% methanol containing 5% glacial acetic acid as an extraction solvent to prepare a test solution; preparing a morphine reference substance solution; according to the method, octadecylsilane chemically bonded silica is taken as a filling agent, acetonitrile and a specific mixed solution are taken as a mobile phase for gradient elution, and determination is carried out under the conditions that the column temperature is 30 DEG C and the detection wavelength is 210 nm. The method is verified by specificity, accuracy, repeatability and the like, the result is reliable, the linear relation is good, a low-toxicity organic reagent is used, the method is environment-friendly, the method can be used as a quality control means of Chinese patent medicines containing poppy shells, and the blank of morphine content determination in the existing standard is filled.

The invention relates to the technical field of medicines, and particularly discloses application of 9-anthraformic acid in preparation of a non-addictive peripheral analgesic medicine. It is proved for the first time that 9-anthracene formic acid has a remarkable analgesic effect and can effectively relieve inflammatory pain, the action target is a peripheral part, central side effects such as addiction and respiratory depression of traditional opioid analgesic are avoided, gastrointestinal injury, cardiovascular risk and curative effect capping effect of non-steroidal anti-inflammatory drugs are also overcome, and the 9-anthracene formic acid can be applied to preparation of anti-inflammatory drugs. Animal experiments prove that the analgesic effect of the compound is comparable with that of classical opioid drug morphine, and a brand new candidate drug and an application direction are provided for developing novel non-addiction analgesic drugs.

The invention belongs to the technical field of medicine, and particularly discloses a preparation method and application of anacycline alkali C and D. The preparation method comprises the following steps: extracting anacycline root medicinal materials by using a mixed solution of acetone and methanol, dissolving by using a hydrochloric acid solution, extracting by using ethyl acetate, adding a saturated sodium bicarbonate solution into an ice-water bath to adjust the pH value, filtering, washing, and drying to obtain the anacycline alkali C and the anacycline alkali D. The preparation method comprises the following steps: extracting the anacycline alkali C and the anacycline alkali D; an alkalized solution is obtained; fully extracting with ethyl acetate and n-butyl alcohol in sequence to obtain crude alkaloid; performing multi-step separation and purification through silica gel column chromatography, MCI gel, Sephadex LH-20 column chromatography, semi-preparative HPLC (High Performance Liquid Chromatography) and the like, and finally performing forward HPLC chiral resolution to obtain a target compound. Activity research shows that the anacycline C and the anacycline D have a remarkable inhibiting effect on mouse writhing reaction caused by acetic acid under the dosage of 5mg / kg, and the analgesic effect of the anacycline C under the dosage of 1mg / kg and 0.2 mg / kg is superior to that of morphine, so that the anacycline C and the anacycline D can be used as novel analgesic lead compounds with development potential.

The invention belongs to the field of medicines, and discloses pyrimido imidazolone derivatives as well as a preparation method and medical application thereof. The pyrimidino imidazolone derivative has a structure as shown in a general formula I. The preparation method comprises the following steps: carrying out substitution reaction on 1-(4-methoxyphenyl)-1-R2-methylamine and a compound 1 under the catalysis of an organic base to obtain a compound 2; carrying out Dieckmann condensation reaction on the compound 2 and excessive CDI to obtain a compound 3; and carrying out Suzuki coupling reaction on the compound 3 and different substituted arylboronic acid or morpholine under the catalysis of sodium carbonate, Pd (OAc) 2 and TPPTS to obtain the pyrimido imidazolone derivative. The pyrimido imidazolone derivative selectively has a strong inhibition effect on proliferation of tumor cells of lung cancer, prostatic cancer, colon cancer, breast cancer, liver cancer and the like, and can be applied to preparation of medicines for treating and / or preventing malignant tumors.

The invention relates to a preparation method of a beta-endarphin (beta-endarphin, human) detection kit using a chemiluminescence immunoassay technology, and particularly relates to a preparation method of a beta-endarphin (beta-endarphin, human) detection kit. Endophalin is also called as brain endophine, is a morphine-like biochemical synthetic hormone and is secreted by pituitary gland. Beta-enorphin is small in molecular weight and poor in immunogenicity and has various structural analogues, so that when a corresponding antibody is prepared, firstly, a proper derivative site needs to be selected, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. The invention mainly relates to the design and synthesis of a beta-enorphin hapten, the preparation of a beta-enorphin complete antigen and an anti-beta-enorphin antibody, a method for measuring the concentration of beta-enorphin, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a beta-ennorphin derivative. The beta-ennorphin derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

A system and methods for medication management and incentivized compliance using a distributed ledger are disclosed. A medication dispenser with a lock, weight sensor, and control unit communicates with a blockchain network executing smart contracts that authorize dispensing events, record authenticated telemetry, and account for tokenized dose entitlements normalized in morphine-milligram equivalents (MME). A prescriber device assigns entitlements to a patient wallet; the dispenser unlocks only upon receipt of an on-chain authorization event that cryptographically binds the requested dose to measured inventory and policy constraints. Post-dispense, signed weight deltas are committed to an authenticated store for audit. Optional risk scoring derived from historical usage features gates dispensing or escalates to multi-party authorization. Unused entitlements may be reconciled under policy via redemption logic. The architecture reduces diversion by coupling cryptographic authorization with tamper-evident telemetry and immutable audit trails.

1. Name of the designed product: MORPHX. 2. Use of the designed product: used as a lying bed in furniture. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: perspective view 1.

The invention relates to a preparation method and application of a compound anacycline B. The compound is prepared by the following steps: crushing an anacycline root medicinal material, soaking in a mixed solvent of acetone and methanol, repeatedly extracting, combining extracting solutions, recovering the solvent to obtain a total extract, dissolving with a hydrochloric acid solution, extracting with ethyl acetate, adding a saturated sodium bicarbonate aqueous solution in an ice-water bath to adjust the pH value, filtering, and drying to obtain the anacycline B; the preparation method comprises the following steps: adding an alkali solution into an alkali solution, respectively extracting with ethyl acetate and n-butyl alcohol to obtain crude alkaloid, carrying out silica gel column chromatography, reversed-phase MCI gel normal-pressure column chromatography, Sephadex LH-20 column chromatography, normal-pressure normal-phase silica gel column chromatography or reversed-phase C-18 column chromatography, carrying out semi-preparative HPLC (High Performance Liquid Chromatography) separation, and carrying out normal-phase HPLC chiral resolution to obtain the compound anacycline B. An analgesic activity test shows that the compound has remarkable analgesic activity on mouse writhing induced by acetic acid under the dosage of 5mg / kg. The morphine derivative has a better analgesic effect than morphine under the dosage of 1mg / kg, can be used as a new drug component or a lead compound of an analgesic, and has a wide development prospect.

Glycosylated, cyclic peptides of Formula (I): A1-cyclo[A2-A3-A4-A5]-A6-O-Carb, Formula (II): A1-cyclo[A5-A3-A4-A2]-A6-O-Carb, and pharmaceutically acceptable salts thereof, are described herein, which are useful, e.g., in treating pain. In some embodiments A1 is L-Tyr; A2 is a D-Lys, D-Orn, D-Dab, or D-Dpr; A3 is L-Trp; A4 is L-Phe, A5 is an amino acid residue selected from the group consisting of Asp, Glu, iso-Asp, and iso-Glu; A6 is (a) a hydroxy-substituted amino acid residue (HO-AA), or (b) an oligopeptide comprising 2 to 5 amino acid residues comprising the HO-AA; Carb is a carbohydrate group bonded to the sidechain oxygen of the HO-AA by a β3-D-glycosidic bond, and the C-terminus of A6 optionally is amidated, e.g., as a primary amide.

The invention belongs to the technical field of adsorption materials, and particularly relates to a nano magnetic adsorption material as well as a preparation method and application thereof. The nano magnetic adsorption material comprises biochar, nano magnetic particles and hydroxyl, the nano magnetic adsorption material is of a nano cluster structure, and the nano magnetic particles are loaded on the biochar and connected with the hydroxyl; wherein the biochar is prepared from shrimp shells. The nanometer magnetic adsorption material can effectively adsorb psychoactive substances, and especially the adsorption efficiency of morphine can reach 98%.

Provided herein are apomorphine compositions comprising an excipient particle and apomorphine nanoparticles, wherein the surface of the excipient particle is coated by Vapor-phase-deposition with the apomorphine nanoparticles. Also provided herein are methods of their preparation and use for treating, preventing, or ameliorating one or more symptoms of a neurological disorder.

Provided are very slightly soluble salts of apomorphine, sustained-release pharmaceutical compositions including the slightly or very slightly soluble salts of apomorphine, and their uses in treating a neurological disease, sexual dysfunction, neuroleptic (-like) malignant syndrome, or an alcohol-related disorder. The very slightly soluble salts of apomorphine are an apomorphine hydroxynaphthoate salt or an apomorphine pamoate salt in a crystal or amorphous form. Also provided are methods for preparing the very slightly soluble salt of apomorphine and its crystal or amorphous form.

The invention relates to the technical field of medicines, in particular to morphine alkaloid compounds, a preparation method and application. The morphine alkaloid compound comprises a compound I and a compound II, poppy shells are used as raw materials, and extraction, resin column chromatography separation and reverse phase silica gel chromatography separation are sequentially carried out by adopting an alcohol solvent to prepare the morphine alkaloid compound. The two compounds have a remarkable inhibition effect on generation of NO stimulated by lipopolysaccharide, can inhibit expression of key media iNOS and COX-2 in inflammatory reaction, and have a good application prospect in the aspect of preparation of anti-inflammatory drugs.

The invention relates to a method of treating a neurological disorder in which an increase in dopaminergic turnover is beneficial, the method comprising intranasal administration of an encapsulated apomorphine composition to a subject in need thereof.

The application provides a method for detecting psychotropic drugs in environmental sludge based on alkaline pretreatment, and comprises the following steps: S1: obtaining a to-be-detected sludge sample, performing pressurized fluid extraction on the to-be-detected sludge sample after freeze-drying to obtain an extraction solution, performing solid-phase extraction on the extraction solution to obtain an elution solution, and redissolving the elution solution to obtain a to-be-detected solution, wherein the pressurized fluid extraction is performed in 1 ‰ ammonia water without heating; and S2: performing liquid chromatography mass spectrometry on the to-be-detected solution to obtain a mass spectrum, and the psychotropic drug is one of morphine, acetylfentanyl and THC-COOH or a combination of two or more thereof, so that the detection of multiple psychotropic drugs in the environmental sludge is realized.

The invention relates to a morphinan type compound as well as a preparation method, a composition and application thereof. Specifically disclosed is a compound I or a pharmaceutically acceptable salt thereof. The morphinan type compound provided by the invention has one or more of the following effects and advantages: (1) the morphinan type compound is relatively high in binding affinity with an opioid receptor; (2) the compound has an obvious agonistic effect on KOR and MOR; (3) the selectivity to a kappa receptor is good; and (4) the ointment has a good treatment effect on inflammatory pain (for example, the ointment takes effect quickly or has an obvious pain effect).

The invention relates to a morphinan compound as well as a preparation method and application thereof, in particular to a morphinan compound as shown in a formula (I), and an isomer, a racemate, a pharmaceutically acceptable salt, a solvate or an isotope label of the morphinan compound. The invention also relates to a preparation method of the compound and a pharmaceutical composition containing the compound and application of the compound in preparation of drugs for preventing and / or treating central nervous system diseases. Compared with a compound disclosed in the prior art, the compound provided by the invention has the advantages of multi-target effect, lower drug dose, less toxic and side effects, better safety and tolerance and the like, is good in comprehensive druggability, and has a good clinical application prospect.

The present invention provides a pholcodine monohydrate synthesis method, and relates to the technical field of chemical combination drug synthesis, commercially available N-(2-chloroethyl) morpholine hydrochloride and morphine base are subjected to a reaction under the alkaline action of potassium carbonate by using acetone as a solvent to obtain a pholcodine target product with high yield. And recrystallizing the crude product in deionized water to obtain a pholcodine monohydrate crystal. Through the combined action of the screening alkali and the solvent, the use of strong alkali such as sodium hydroxide is avoided, and the reaction safety is improved; in addition, through recrystallization of the product in water, not only is the pholcodine monohydrate successfully synthesized, but also the effect of further purifying the compound is achieved.

The invention discloses a chemical enzyme preparation method and application of alkaloid, and belongs to the technical field of bioengineering. According to the invention, the (S)-tetrahydropapaverine and the derivative thereof are efficiently synthesized by utilizing an artificially designed multi-enzyme cascade reaction, and tetrahydroprotoberberine, aporphine, morphine dienone alkaloid and the derivative thereof are synthesized by using a chemical method. According to the invention, key enzymes of a synthetic route are respectively expressed in escherichia coli BL21, BL21-1, BL21-2 and BL21-3 are constructed, and (S)-tetrahydropapaverine and derivatives thereof are synthesized by using the strains. The (S)-tetrahydropapaverine and the derivative thereof prepared by the method disclosed by the invention can be further catalytically synthesized into alkaloids such as tetrahydroprotoberberine, aporphine and morphine dienone through a chemical method, and the (S)-tetrahydropapaverine and the derivative thereof have a wide application prospect.

The invention discloses a morpholine organophosphine ligand and its preparation method and application. The preparation method of the morpholine organophosphine ligand comprises the following steps: under nitrogen conditions, adding m-dibromobenzene, morpholine, an inorganic base, and a first catalyst to a reactor; using tetrahydrofuran as a reaction solvent; reacting at 45 to 55° C. for 5 to 7 hours; then reducing the reaction temperature to 75 to 80° C.; adding n-butyl lithium; stirring; raising the reaction temperature to 0° C.; adding a second catalyst and a halophosphine reagent; and reacting to obtain the morpholine organophosphine ligand. The present invention adopts the above-mentioned morpholine organophosphine ligand and its preparation method and application to provide a method for synthesizing a novel morpholine organophosphine ligand under mild conditions. The morpholine organophosphine ligand is successfully applied to a Pd-catalyzed C-N bond formation reaction, showing high efficiency and selectivity, simplifying the reaction conditions, and broadening the scope of application.